Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPA006
- Development stage
- Preclinical
- Lead developer
- Logan Natural Products
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CPA006 is a small molecule cyclopamine derivative that acts as an inhibitor of the Hedgehog (Hh) signaling pathway. Developed as a more soluble and efficacious alternative to naturally occurring cyclopamine, it targets the Smoothened (SMO) protein to block Hh-mediated carcinogenesis. Research presented at AACR 2010 demonstrated its efficacy in reducing tumor mass and decreasing Hh target gene expression in mouse models of basal cell carcinoma (BCC) and pancreatic cancer. It has been studied for topical application in skin dysplasia and systemic or orthotopic treatment in pancreatic cancer models.
- Other names
- cyclopamine derivative CPA006
02
Targets
SMO (Smoothened)
Beyond the preview
Go deeper on CPA006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPA006.